Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Targeting leukemic stem cells by Bcl-2 inhibition

20.11.2006
Study in laboratory cell cultures, patient samples shows promise

Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.

The drug was powerful in its own right, the researchers say, but they found that some AML cells were themselves resistant to ABT-737, so they added another drug that knocked out this secondary resistance. Together, these agents may provide a powerful therapy against AML, and could form the basis of a new way to treat the cancer, say the scientists, whose study was published in the November 14 issue of the journal, Cancer Cell.

"The combination of these two experimental drugs provides the highest synergistic action I have ever seen against acute myeloid leukemia cells," said the study's lead author, Michael Andreeff, M.D., Ph.D., professor in the Departments of Stem Cell Transplantation and Leukemia.

... more about:
»ABT-737 »AML »Andreeff »Bcl-2 »Mcl-1 »Protein »chemotherapy »leukemia

Although the study was done in laboratory cell cultures and AML cells obtained from patients, Andreeff said he hopes that a combination of these two agents could be tested in eligible patients when they receive standard chemotherapy treatment. "ABT-737 would overcome resistance to chemotherapy that we often see in AML therapy, and the second drug would overcome resistance to ABT-737," he said.

"ABT-737 represents a completely new class of agents that could have a major impact on a number of cancers, and we have now seen that AML will likely be among them," Andreeff added.

The successful use of ABT-737 in animal models of human small-cell lung cancer and cancers of the lymph system were reported in 2005 by researchers from Abbott Laboratories, which developed the compound.

The agent works by manipulating members of the BCL-2 family of proteins, which includes both pro-apoptotic and anti-apoptotic molecules. (Apoptosis is a process whereby a cell kills itself because it is seriously injured or growing out of control).

ABT-737 targets the best-known member of the group, also called BCL-2, which is a cell "survival" protein that is over-expressed in many types of cancer. This protein prevents a cell from committing apoptosis by latching on to other BCL-2 family member proteins that promote cell death, thus rendering them ineffective. ABT-737, however, was engineered to fit tightly on to BCL-2, occupying that binding space so that the other pro-apoptotic proteins can function and promote cell death.

In this study, Andreeff and a team of researchers found that ABT-737 "potently" kills AML cell lines as well as blast cells taken from AML patients. "Most importantly, our results demonstrated killing of the progenitor and stem cells responsible for production of AML, which makes this a truly innovative treatment for different leukemias and cancer," Andreeff said.

However, AML cells in which another anti-apoptotic protein known as MCL-1 is over expressed did not die, which makes this protein a "resistance factor" to ABT-737 and to standard chemotherapy, he said. "In myeloid leukemia, MCL-1 can be more important than BCL-2 because when a cell has a significant amount of MCL-1, many drugs don't work," said Andreeff. In fact, he added, patients whose cells over-express MCL-1 were found by his group to have a poorer outcome.

So, the researchers added an experimental drug, a MAP-kinase inhibitor, to knock down MCL-1 expression, and found that this inhibitor also worked to inhibit cells in which BCL-2 is phosphorylated, which can switch a protein on or off. "ABT-737 had diminished effects against cells with phosphorylated BCL-2, which was restored by combination with a MAPK inhibitor," Andreeff said.

The study helps refine the understanding of the effects of ABT-737 on cancer cells, he said.

By using knock-out technology, the researchers also found that in leukemia cells, ABT-737 was dependent on two proteins called BAX and BAK to trigger apoptosis. Other researchers have said that the critical partner to ABT-737 was a similar protein known as BIM. "Both of these proteins poke holes in a cell mitochondria and release proteins that initiate cell death, but it is important to know that BAX and BAK are the important players," he said.

Andreeff said that the next step for M. D. Anderson researchers is to test ABT-737 in patients with leukemias.

Julie A. Penne | EurekAlert!
Further information:
http://www.mdanderson.org

Further reports about: ABT-737 AML Andreeff Bcl-2 Mcl-1 Protein chemotherapy leukemia

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>